Drug Therapy
Drugs are approved in the U.S. by the Food and Drug Administration (FDA) for specific purposes to help guide medical practice.
Currently, there are no FDA approved drugs specifically for the treatment of HHT. However, there have been several promising studies and positive results for medications originally developed to treat other conditions.
Related Resources
HHT Scientific Conference Summaries (recorded)
Webinar – 2018Drs. Hughes, Faughnan and Andrejecsk provide a first hand synopsis of the HHT science presented in Dubrovnik, Croatia where over 200 voices were heard from 23 countries. They reviewed the 12th HHT International Conference Executive Summary of…
MoreExecutive Summary – 12th HHT International Scientific Conference (2017)
Scientific Literature – 2017Angiogenesis. Authors: Jillian W. Andrejecsk, Anna E. Hosman, Luisa M. Botella, Claire L. Shovlin, Helen M. Arthur, Sophie Dupuis-Girod, Elisabetta Buscarini, Christopher C. W. Hughes, Franck Lebrin, Christine L. Mummery, Marco C. Post, and Johannes…
More
Hazardous Natural Health Products in HHT
Article – 2017HHT patients can bleed easily, which is why products that may thin your blood or reduce your ability to clot can be very dangerous. This handout was developed by Daniel Cortes, Pharmacist at the St. Michael’s Hospital HHT Center in Toronto, Canada, t…
More
FDA Food and Drug Interactions
Article – 2017What you eat and drink can affect the way your medicines work. Use this guide to alert you to possible “food-drug interactions” and to help you learn what you can do to prevent them. This guide covers interactions between some common prescription and…
MoreEffect of Bevacizumab Nasal Spray on Epistaxis Duration in HHT. A Randomized Clinical Trial
Scientific Literature – 2016JAMA. Authors: Sophie Dupuis-Girod, PhD, Alexis Ambrun, MD, and Evelyne Decullier, PhD. This article is available for public use and does not require purchase. Click to view the full article.
MoreExecutive Summary – 11th HHT International Scientific Conference (2015)
Scientific Literature – 2015Angiogenesis. Authors: Helen Arthur, Urban Geisthoff, James R. Gossage, Christopher C. W. Hughes, Pascal Lacombe, Mary E. Meek, Paul Oh, Beth L Roman, Scott O. Trerotola, Sebastiaan Velthuis, and Whitney Wooderchak-Donahue. This article can be purcha…
MoreIntravenous Bevacizumab for Complications of HHT: A Review of Literature
Scientific Literature – 2015International Forum of Allergy & Rhinology. Authors: Natalia P. Arizmendez, Luke Rudmik, and David M. Poetker. This article can be purchased directly from the publisher. Click to view the article description and purchase options.
More
Dose-Response Relationship of Bevacizumab in HHT
Scientific Literature – 2015Mabs. Authors: Nicolas Azzopardi, Sophie Dupuis-Girod, David Ternant, Anne-Emmanuelle Fargeton, Isabelle Ginon, Frédéric Faure, Evelyne Decullier, Adeline Roux, Marie-France Carette, Brigitte Gilbert-Dussardier, Pierre-Yves Hatron, Pascal Lacombe, Va…
MoreVEGF Neutralization can Prevent and Normalize Arteriovenous Malformations in an Animal Model for HHT2
Scientific Literature – 2014Angiogenesis. Authors: Chul Han, Se-Woon Choe, Yong Hwan Kim, Abhinav P. Acharya, Benjamin G. Keselowsky, Brian S. Sorg, Young-Jae Lee, and S. Paul Oh. This article is available for public use and does not require purchase. Click to view the full art…
MoreHereditary Hemorrhagic Telangiectasia: From Molecular Biology to Patient Care
Scientific Literature – 2010Journal of Thrombosis and Haemostasis. Authors: S. Dupuis-Girod, S. Bailly, and H. Plauchu. This article is available for public use and does not require purchase. Click to view the full article.
MoreRelated News
67th ASH Annual Meeting and Exposition
67th ASH Annual Meeting and Exposition December 5-9, 2025 Mark your calendars and get ready to join Cure HHT at the 67th ASH Annual Meeting and Exposition. We will be hosting a Friday Satellite Sympos…
2025 HHT Patient and Physician National Conference
July 23, 2025
Recording Available: Empowering Patient Stories
June 3, 2025
Cozy Games for a Cure
June 3, 2025